Antibody Responses to EBV and Toxoplasma and Their Genetic Links to Guillain-Barré Syndrome: A Mendelian Randomization Study

Overview

Journal Brain Behav

Date 2025 Feb 10

PMID 39924945

Authors

Xiangjia Qi

Liqian Gao

Lifeng Qi

Affiliations

Soon will be listed here.

Abstract

Background: This study aims to investigate the potential causal relationship between antibody-mediated immune responses to infectious agents and Guillain-Barré syndrome (GBS) using a two-sample Mendelian randomization (MR) approach.

Methods: Publicly available summary data from genome-wide association studies (GWAS) were utilized for comprehensive analysis. A genome-wide and human leukocyte antigen association study conducted by Guillaume Butler-Laporte et al. (n = 9724) examined 46 types of antibody-mediated immune responses. GWAS summary statistics for GBS were obtained from the FinnGen consortium (n = 215,931) comprising European populations. The primary method for MR analysis was the inverse-variance weighted (IVW) method. Various sensitivity analyses were conducted to assess the heterogeneity and pleiotropy of the findings.

Results: The IVW method indicates a negative correlation between elevated levels of Epstein-Barr virus (EBV) viral capsid antigen (VCA) p18 antibody and the risk of GBS (OR = 0.79, 95% confidence interval [CI]: 0.65-1.85, p = 0.012). Elevated levels of Toxoplasma gondii surface antigen 1 (sag1) antibody also show a negative correlation with the risk of GBS (OR = 0.79, 95% CI: 0.67-0.92, p = 0.003). No evidence of heterogeneity or horizontal pleiotropy was found in the MR analysis.

Conclusions: Elevated levels of EBV VCA p18 and T. gondii sag1 antibodies appear to be negatively correlated with the risk of GBS, suggesting that immune responses to these pathogens may play a protective role. However, the CI for the EBV VCA p18 association includes 1, indicating the need for caution in interpreting this result. Further research, including mechanistic studies and broader immune profiling, is needed to confirm these findings and explore the underlying pathways.

References

Gonzalez M, Caballero D, Lopez C, Alburquerque T, Hernandez R, De La Loma A . Cerebral toxoplasmosis and Guillain-Barré syndrome after allogeneic peripheral stem cell transplantation. Transpl Infect Dis. 2001; 2(3):145-9. DOI: 10.1034/j.1399-3062.2000.020308.x. View

Seng S, Makala L, Yokoyama M, Lim C, Choi Y, Suzuki N . SAG1 is a host-targeted antigen for protection against toxoplasma gondii infection. Pathobiology. 2004; 71(3):144-51. DOI: 10.1159/000076469. View

Florian I, Lupan I, Sur L, Samasca G, Timis T . To be, or not to be… Guillain-Barré Syndrome. Autoimmun Rev. 2021; 20(12):102983. DOI: 10.1016/j.autrev.2021.102983. View

Kasper L, Khan I . Role of P30 in host immunity and pathogenesis of T. gondii infection. Res Immunol. 1993; 144(1):45-8. DOI: 10.1016/s0923-2494(05)80097-5. View

Karsten C, Bartsch Y, Shin S, Slein M, Heller H, Kolandaivelu K . Evolution of functional antibodies following acute Epstein-Barr virus infection. PLoS Pathog. 2022; 18(9):e1010738. PMC: 9481173. DOI: 10.1371/journal.ppat.1010738. View

Pierce B, Ahsan H, VanderWeele T . Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int J Epidemiol. 2010; 40(3):740-52. PMC: 3147064. DOI: 10.1093/ije/dyq151. View

Pagheh A, Sarvi S, Sharif M, Rezaei F, Ahmadpour E, Dodangeh S . Toxoplasma gondii surface antigen 1 (SAG1) as a potential candidate to develop vaccine against toxoplasmosis: A systematic review. Comp Immunol Microbiol Infect Dis. 2020; 69:101414. DOI: 10.1016/j.cimid.2020.101414. View

Zhou L, Peng J, Chen M, Yao L, Zou W, He C . SAG1 targeting host cell S100A6 for parasite invasion and host immunity. iScience. 2021; 24(12):103514. PMC: 8671940. DOI: 10.1016/j.isci.2021.103514. View

Islam B, Islam Z, GeurtsvanKessel C, Jahan I, Endtz H, Mohammad Q . Guillain-Barré syndrome following varicella-zoster virus infection. Eur J Clin Microbiol Infect Dis. 2018; 37(3):511-518. DOI: 10.1007/s10096-018-3199-5. View

10.

Willison H, Jacobs B, van Doorn P . Guillain-Barré syndrome. Lancet. 2016; 388(10045):717-27. DOI: 10.1016/S0140-6736(16)00339-1. View

11.

Bowden J, Davey Smith G, Haycock P, Burgess S . Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol. 2016; 40(4):304-14. PMC: 4849733. DOI: 10.1002/gepi.21965. View

12.

Rodriguez Y, Rojas M, Pacheco Y, Acosta-Ampudia Y, Ramirez-Santana C, Monsalve D . Guillain-Barré syndrome, transverse myelitis and infectious diseases. Cell Mol Immunol. 2018; 15(6):547-562. PMC: 6079071. DOI: 10.1038/cmi.2017.142. View

13.

Ferraro D, Galli V, Simone A, Bedin R, Vitetta F, Merelli E . Cerebrospinal fluid anti-Epstein-Barr virus specific oligoclonal IgM and IgG bands in patients with clinically isolated and Guillain-Barré syndrome. J Neurovirol. 2016; 23(2):329-334. DOI: 10.1007/s13365-016-0493-9. View

14.

Damania B, Kenney S, Raab-Traub N . Epstein-Barr virus: Biology and clinical disease. Cell. 2022; 185(20):3652-3670. PMC: 9529843. DOI: 10.1016/j.cell.2022.08.026. View

15.

Blackwell J, Jamieson S, Burgner D . HLA and infectious diseases. Clin Microbiol Rev. 2009; 22(2):370-85, Table of Contents. PMC: 2668228. DOI: 10.1128/CMR.00048-08. View

16.

Readhead B, Haure-Mirande J, Funk C, Richards M, Shannon P, Haroutunian V . Multiscale Analysis of Independent Alzheimer's Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus. Neuron. 2018; 99(1):64-82.e7. PMC: 6551233. DOI: 10.1016/j.neuron.2018.05.023. View

17.

Nyati K, Nyati R . Role of Campylobacter jejuni infection in the pathogenesis of Guillain-Barré syndrome: an update. Biomed Res Int. 2013; 2013:852195. PMC: 3755430. DOI: 10.1155/2013/852195. View

18.

Bossi P, Caumes E, Paris L, Darde M, Bricaire F . Toxoplasma gondii-associated Guillain-Barré syndrome in an immunocompetent patient. J Clin Microbiol. 1998; 36(12):3724-5. PMC: 105275. DOI: 10.1128/JCM.36.12.3724-3725.1998. View

19.

Velge-Roussel F, Chardes T, Mevelec P, Brillard M, Hoebeke J, Bout D . Epitopic analysis of the Toxoplasma gondii major surface antigen SAG1. Mol Biochem Parasitol. 1994; 66(1):31-8. DOI: 10.1016/0166-6851(94)90033-7. View

20.

Budiningsih I, Verkuijlen S, Dachlan Y, Arfijanto M, Hadi U, Middeldorp J . EBV-IgA antibody responses in endemic and nonendemic populations with nasopharyngeal carcinoma: tumour marker prognostication study and a cross-sectional study. Ann Med Surg (Lond). 2023; 85(9):4394-4403. PMC: 10473314. DOI: 10.1097/MS9.0000000000000963. View